The pharmacological principles governing sedative-hypnotic drug action are not uniform across the human lifespan, and their clinical application requires substantial modification when prescribing for populations whose pharmacokinetics, pharmacodynamics, developmental physiology, or clinical context differ substantially from the typical adult patient. This final module addresses the populations and clinical settings in which these modifications matter most: pediatric patients requiring procedural sedation; neonates and infants with unique GABA-A receptor (GABA-A) physiology; elderly patients with compounded pharmacokinetic and pharmacodynamic vulnerability; patients with concurrent substance use disorders where risk stratification and agent selection differ critically; primary care clinicians managing benzodiazepine-dependent patients without specialist support including in rural settings; and reproductive-age patients in whom fetal and neonatal exposure must be weighed against maternal treatment needs.
Throughout this module the emphasis is on clinically actionable decision-making: which agents to choose, which to avoid, what dose adjustments to make, and how to structure monitoring in populations where the consequences of pharmacological misjudgment are most severe. The content integrates the pharmacokinetic and mechanistic principles from CNS-01 through CNS-05, applying them to the clinical scenarios that constitute the most challenging prescribing decisions in sedative-hypnotic pharmacology.
Children are not simply small adults. In neonates (0–28 days), CYP3A4 (cytochrome P450 3A4) activity is approximately 30–40% of adult levels at birth, reaching adult levels by 6–12 months. Glucuronidation capacity is similarly reduced, reaching adult capacity by 2–3 years. Renal GFR is markedly reduced in neonates (approximately 20–30 mL/min/1.73m² versus adult 100–120 mL/min/1.73m²) and reaches adult levels by 6–12 months, prolonging elimination of renally cleared active metabolites such as 1-hydroxymidazolam glucuronide.1 In contrast, older infants and young children (1–10 years) often have higher weight-normalized hepatic clearance than adults due to proportionally larger liver mass, producing higher mg/kg dose requirements. Reduced plasma albumin in neonates increases free drug fraction, amplifying pharmacological effect at any given total plasma concentration.
Oral midazolam (0.3–0.5 mg/kg, maximum 15–20 mg) is the most widely used agent for pediatric procedural anxiolysis, providing reliable sedation within 15–30 minutes. Intranasal midazolam (0.2–0.3 mg/kg, maximum 10 mg) provides more rapid onset (5–10 minutes) and is useful when oral administration is difficult, though bioavailability is variable (50–83%) and nasal irritation can occur.2 Intranasal dexmedetomidine (1–2 mcg/kg) has emerged as an important alternative, producing reliable sedation within 25–45 minutes with analgesia alongside anxiolysis and no respiratory depression at standard doses — making it suitable for settings where advanced airway personnel are not immediately available.3 Bradycardia requires monitoring. Ketamine (1–2 mg/kg IV or 3–5 mg/kg IM) is the agent of choice for procedures requiring both analgesia and sedation in the emergency setting, with a wide therapeutic index in children and lower emergence reaction rates than adults. Propofol provides excellent sedation and rapid recovery but requires personnel with advanced airway training. The decline of chloral hydrate from pediatric sedation practice reflects its narrow therapeutic index, cardiac arrhythmia risk, and carcinogenic metabolite concerns.
A dedicated monitoring provider separate from the proceduralist is mandatory. Continuous pulse oximetry, cardiac monitoring, and capnography for moderate and deep sedation are required. Pre-sedation assessment must include weight in kilograms, nil per os — nothing by mouth (NPO) status, Mallampati score in cooperative children, and identification of conditions increasing sedation risk (obstructive sleep apnea (OSA), craniofacial abnormalities, reactive airway disease, congenital heart disease). Appropriately sized airway equipment must be immediately available and checked before sedation. Reversal agents must be drawn and ready before initiation. Post-sedation recovery must meet age-appropriate discharge criteria including return to pre-sedation level of consciousness, stable vital signs, and resumption of age-appropriate activity and communication.2
One of the most clinically important counterintuitive principles in neonatal neuropharmacology is that GABA-A receptor activation produces neuronal depolarization (excitation) rather than hyperpolarization (inhibition) in the immature brain. This developmental reversal occurs because neonatal neurons express high intracellular chloride concentrations mediated by high sodium-potassium-chloride cotransporter 1 (NKCC1) co-transporter expression and low potassium-chloride cotransporter 2 (KCC2) expression. When GABA-A receptor-gated chloride channels open, chloride exits the neonatal neuron (rather than entering as in adults), producing membrane depolarization.4 This reversal means GABAergic agents — including benzodiazepines — may have reduced or even paradoxically excitatory effects in neonatal neurons, partially explaining why phenobarbital (which additionally antagonizes AMPA glutamate receptors) is more effective than benzodiazepines alone for neonatal seizures. The NKCC1/KCC2 ratio shifts progressively toward the adult pattern over the first weeks to months of life.
Neonatal seizures occur in approximately 1–5 per 1,000 live births, most commonly from hypoxic-ischemic encephalopathy, ischemic stroke, intracranial hemorrhage, metabolic disturbances, and meningitis. Accurate diagnosis increasingly relies on amplitude-integrated EEG or continuous EEG monitoring, as a substantial proportion of neonatal seizures are subclinical.4 Phenobarbital remains first-line therapy, with IV loading doses of 20 mg/kg (maximum 40 mg/kg total) achieving seizure control in approximately 40–60% of neonates. When phenobarbital fails, second-line options include fosphenytoin (20 mg PE/kg IV) and levetiracetam (40–60 mg/kg IV, supported by the Neonatal Seizure Treatment with Medication Off-Patent trial, phase 2 (NEOLEV2) randomized trial). Benzodiazepines are used as third-line agents. Phenobarbital's superior efficacy over benzodiazepines in neonates reflects precisely the GABA-A polarity reversal described above — its additional AMPA receptor antagonism suppresses excitatory neurotransmission independently of immature GABAergic inhibition.
Neonatal abstinence syndrome (NAS) from sedative-hypnotic exposure follows the same pathophysiology as opioid NAS: receptor neuroadaptation in the fetus produces a withdrawal syndrome when placental drug delivery ceases at birth.5 Benzodiazepine (BZD)-NAS typically manifests within 24–72 hours and includes irritability, tremulousness, high-pitched crying, poor feeding, and in severe cases seizures. Non-pharmacological management is first-line: minimizing environmental stimulation, skin-to-skin care, swaddling, and frequent small-volume feedings. Pharmacological treatment with phenobarbital is initiated when Finnegan scoring thresholds are exceeded, providing smooth GABA-A modulation with a self-tapering pharmacological profile from its long half-life. Weaning reduces doses by 10–20% every 24–48 hours as scores remain controlled, with treatment typically lasting 1–3 weeks.
All benzodiazepines cross the placenta readily due to lipophilicity and low molecular weight, with fetal plasma concentrations approaching maternal levels for diazepam within minutes of IV administration. Long-acting agents with active metabolites produce the most significant neonatal pharmacological burden at delivery. Benzodiazepines are detectable in breast milk with milk-to-plasma ratios varying by agent: diazepam 0.1–0.3, lorazepam approximately 0.15, oxazepam and temazepam lower due to higher protein binding and shorter half-lives. Neonates nursing from mothers on benzodiazepines may receive pharmacologically active doses through breast milk, particularly with long-acting agents. Periodic assessment of the breastfed infant for sedation, poor feeding, and weight gain is appropriate when maternal benzodiazepine use during lactation is unavoidable.5
Hepatic blood flow decreases by approximately 30–40% between ages 25 and 75, reducing first-pass metabolism and increasing bioavailability of high-extraction-ratio drugs. Phase I hepatic metabolism (cytochrome P450 (CYP450)-dependent oxidation) is reduced by 20–40% in older adults, substantially prolonging half-lives of CYP-dependent benzodiazepines (diazepam, chlordiazepoxide, alprazolam, triazolam). Phase II metabolism (glucuronidation) is relatively preserved, explaining the preference for LOT agents in elderly patients.6 Renal function declines approximately 1 mL/min/1.73m² per year after age 40, reducing clearance of active metabolites. Plasma albumin decreases with aging, increasing the free fraction of highly protein-bound drugs. Body fat-to-lean mass ratio increases with age, enlarging the volume of distribution of lipophilic drugs and creating an adipose reservoir that extends drug action beyond the nominal half-life — diazepam's effective half-life in elderly patients may reach 5–7 days from adipose redistribution.
Aging produces clinically significant increases in CNS sensitivity to sedative-hypnotic drugs independent of pharmacokinetic changes. Age-related neuronal loss (particularly prefrontal cortex and hippocampus), altered GABA-A receptor (GABA-A) expression and subunit composition, and reduced compensatory mechanisms for managing drug-induced CNS depression collectively produce disproportionate sedation, cognitive impairment, and psychomotor impairment in elderly patients at plasma drug concentrations well-tolerated in younger adults. EEG studies demonstrate greater CNS effect per unit drug concentration in elderly subjects across multiple sedative-hypnotic classes.6
The American Geriatrics Society (AGS) Beers Criteria list all benzodiazepines and most Z-drugs as medications to avoid in adults aged 65 and older. Evidence supporting this recommendation includes independently established associations with falls and hip fractures (relative risk approximately 1.5–2.0), motor vehicle accidents, cognitive impairment clinically indistinguishable from early dementia in some patients, and increased dementia incidence in multiple large epidemiological cohort studies.7 Reversibility of cognitive impairment after benzodiazepine discontinuation is clinically important and motivationally useful: prospective studies demonstrate measurable improvement in memory, processing speed, and executive function within 1–3 months of successful taper — a benefit worth communicating explicitly to patients and families when initiating deprescribing discussions.
When benzodiazepines are unavoidable in elderly patients, LOT agents are strongly preferred: lorazepam 0.25–0.5 mg, oxazepam 7.5 mg, or temazepam 7.5 mg represent appropriate starting doses in patients over 75 (25–50% of standard adult doses). For insomnia, ramelteon 8 mg and low-dose doxepin 3 mg are preferred non-scheduled alternatives. DORAs at lowest available doses (suvorexant 5 mg, lemborexant 5 mg) are reasonable for elderly patients with insomnia when non-scheduled agents are insufficient, given their more favorable fall and cognitive profile compared to Z-drugs and benzodiazepines.6,7
Systematic reviews consistently show structured taper programs achieve successful discontinuation in 40–80% of long-term users, with highest success rates when combined with CBT for anxiety or insomnia and motivational interviewing. A landmark randomized trial demonstrated that a single structured physician letter explicitly recommending benzodiazepine reduction produced significant reductions in use at 6-month follow-up — a low-effort intervention that should be incorporated into routine care for any elderly patient on chronic benzodiazepine therapy.8 The standard approach is conversion to diazepam equivalents followed by a gradual structured taper (5–10% per 1–2 weeks, slowing to 5% or less per 2 weeks as dose decreases). Total taper duration in elderly patients with decades of use may appropriately extend to 6–24 months, and there is no clinical benefit and significant harm in rushing this process.
Patients with substance use disorders represent a high-risk population for sedative-hypnotic prescribing. They are at substantially elevated risk for benzodiazepine use disorder yet frequently have legitimate indications requiring pharmacological management. Effective risk assessment should include: screening for current and historical substance use disorder (SUD) (Alcohol Use Disorders Identification Test — Consumption (AUDIT-C), Drug Abuse Screening Test, 10-item version (DAST-10), specific inquiry about prior benzodiazepine misuse); prescription drug monitoring program (PDMP) review; urine drug screen where indicated; and assessment of the current SUD treatment context including any medication-assisted treatment.9
Patients on buprenorphine/naloxone or methadone for opioid use disorder represent a specific high-risk group. Buprenorphine's ceiling effect on respiratory depression is partially overcome by concurrent benzodiazepines; multiple case series document fatal respiratory depression from this combination in patients who would have been protected by buprenorphine's ceiling effect alone. The FDA label for buprenorphine carries a black box warning for concurrent benzodiazepine use.9 Methadone carries even greater risk given its full mu-agonist profile and QTc prolongation. When anxiety or insomnia requires treatment in MAT patients, non-scheduled agents are the default: SSRIs/SNRIs for anxiety, ramelteon or low-dose doxepin for insomnia, and hydroxyzine (25–50 mg, no dependence potential) for acute anxiolysis as an evidence-supported off-label option. If a scheduled agent is unavoidable, close coordination with the prescribing MAT provider is mandatory.
Benzodiazepines are clearly indicated and potentially life-saving for alcohol withdrawal syndrome, where the risks of undertreatment — withdrawal seizures, delirium tremens, death — substantially exceed the risks of appropriate use. Long-acting benzodiazepines (diazepam, chlordiazepoxide) with symptom-triggered Clinical Institute Withdrawal Assessment for Alcohol, Revised (CIWA-Ar)-guided dosing are standard. After the acute withdrawal period (typically 5–7 days), benzodiazepines should be tapered and discontinued rather than continued for anxiety treatment in patients with alcohol use disorder (AUD) — chronic use is associated with higher relapse rates, greater psychiatric comorbidity severity, and increased mortality. Evidence-based AUD maintenance pharmacotherapy (naltrexone, acamprosate, disulfiram) should be initiated during or immediately after withdrawal management.9
Rates of gabapentinoid misuse in SUD populations are reported at 15–22% in some addiction treatment series, driven by euphoriant properties, anxiolysis, and opioid potentiation. Prescribers caring for patients with SUD should include gabapentinoids in PDMP surveillance where scheduled. When prescribed for legitimate indications in SUD patients, the lowest effective dose, defined treatment duration, and close follow-up are warranted.9
The majority of benzodiazepine prescribing occurs in primary care settings, and in rural and underserved communities the primary care clinician often serves as the de facto specialist for sedative-hypnotic-related clinical problems — without ready access to psychiatry or addiction medicine consultation.10 Understanding how to identify, assess, manage, and safely deprescribe benzodiazepines without specialist backup is an essential clinical competency, particularly for rural practitioners serving geographically isolated patient populations.
Red flags warranting systematic assessment include: requests for early refills or reports of lost prescriptions; requests for dose escalation without clear clinical justification; concurrent opioid prescriptions on Prescription Drug Monitoring Program (PDMP) review; evidence of multi-provider prescribing; patient resistance to dose reduction; functional deterioration attributed to benzodiazepine use; and evidence of concurrent alcohol use. Systematic PDMP review before any benzodiazepine prescription or refill is both a legal requirement in most states and the most effective tool for identifying dangerous drug combinations and multi-provider prescribing.10
Key principles supported by behavioral medicine evidence include: leading with the patient's own health goals rather than regulatory concerns; framing dose reduction as an active intervention to improve function (cognitive clarity, sleep quality, coordination); explicitly acknowledging the difficulty of dose reduction; establishing that the process will be gradual and patient-paced; and providing educational materials. Evidence from randomized trials confirms that even a brief structured physician-initiated conversation — as short as 5 minutes with a follow-up letter — produces significant reductions in benzodiazepine use at 6 months compared to usual care.8 This low-resource intervention should be a standard part of chronic benzodiazepine management.
Essential steps include: full assessment of current use (agent, dose, duration, prior withdrawal history, concurrent substances); conversion to diazepam equivalents if the patient is on a short-acting high-potency agent; a written taper plan agreed with the patient; initiation of selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) for underlying anxiety; referral to cognitive behavioral therapy for insomnia (CBT-I) for insomnia; close follow-up every 1–2 weeks during active dose changes; and clear criteria for when specialist consultation or inpatient detoxification is needed. Indications for specialist referral include prior severe withdrawal with seizures or delirium, very high doses (≥40 mg diazepam equivalents/day), concurrent high-dose opioid use, severe comorbid psychiatric illness, and failed outpatient taper attempts. Telehealth-connected addiction medicine or psychiatry consultation is an increasingly available resource for rural clinicians facing complex deprescribing scenarios.10
Community pharmacists are underutilized allies, particularly in rural communities where the pharmacist may know patients personally and have longitudinal dispensing records revealing concerning patterns before the prescriber becomes aware. Proactive communication with the dispensing pharmacy about taper plans and monitoring parameters for early refill requests strengthens the safety net around high-risk patients. Digital CBT-I programs (Sleepio, Somryst) and teletherapy platforms expand access to behavioral interventions for rural patients where in-person therapy is unavailable.
The teratogenic risk of benzodiazepines has been debated since early case reports in the 1970s suggested an association with oral cleft defects. Subsequent controlled epidemiological studies have produced conflicting results: some large cohort studies find modest increases in oral cleft risk (absolute risk increase from approximately 0.06% baseline to 0.07–0.1%) while others find no significant association after controlling for confounders including maternal anxiety disorder severity.11 The current evidence does not establish a clear causal relationship between benzodiazepine exposure and major structural teratogenicity at therapeutic doses, but absence of definitive evidence of harm is not evidence of safety, and minimizing unnecessary exposure during organogenesis (first trimester) remains appropriate practice. Second and third trimester exposure is associated with fetal growth restriction and preterm birth in some studies. Third trimester use most clearly produces neonatal effects: neonatal abstinence syndrome, neonatal hypotonia ("floppy infant syndrome"), hypothermia, and respiratory depression requiring NICU admission in severe cases. Neonatal effects are directly proportional to dose, half-life, and duration of maternal use.
For acute seizures in pregnancy including eclamptic seizures and status epilepticus, the benefits of benzodiazepine treatment clearly outweigh fetal risks. IV lorazepam (0.1 mg/kg, maximum 4 mg) or IV diazepam (0.15–0.2 mg/kg) are appropriate first-line treatments for status epilepticus in pregnancy; the risk of maternal hypoxia and acidosis from untreated seizures substantially exceeds the risk of acute benzodiazepine exposure. Magnesium sulfate remains the agent of choice for eclampsia prophylaxis and seizure management in the eclampsia context specifically, as it does not carry the neonatal CNS depression concerns of benzodiazepines at clinically used doses.
For women with pre-existing anxiety disorders requiring pharmacological management during pregnancy, SSRIs and SNRIs are the preferred first-line agents after careful risk-benefit discussion, with more extensive and generally reassuring safety data compared to benzodiazepines. Buspirone has not been associated with teratogenicity in limited human data, though the evidence base is insufficient for confident use. Short-term low-dose benzodiazepines may be appropriate in specific clinical situations (severe acute panic during selective serotonin reuptake inhibitor (SSRI) latency period) with the shortest possible duration and explicit risk-benefit documentation. Non-pharmacological approaches including CBT, mindfulness-based therapy, and structured relaxation should be first-line for anxiety management in pregnancy whenever clinically feasible.11
Benzodiazepines are present in breast milk with milk-to-plasma ratios varying by agent. Short-acting agents without active metabolites (lorazepam, oxazepam) are preferred when benzodiazepine use during lactation is unavoidable, as their lower milk-to-plasma ratios and absence of accumulating metabolites minimize infant exposure. Diazepam is the least suitable agent during breastfeeding given its high milk-to-plasma ratio (0.1–0.3) and long-acting active metabolites. If benzodiazepine use during lactation cannot be avoided, timed administration (immediately after feeding, allowing maximum time before the next feed for drug clearance) and close monitoring of the infant for sedation, poor feeding, and weight gain are appropriate measures.11 An important pharmacological interaction relevant to reproductive-age patients on benzodiazepines is phenobarbital's potent cytochrome P450 3A4 (CYP3A4) and CYP2C9 (cytochrome P450 2C9) induction, which substantially reduces the efficacy of combined hormonal contraceptives containing ethinyl estradiol. Women of reproductive age prescribed phenobarbital — whether for seizure management, alcohol withdrawal, or neonatal abstinence syndrome (NAS) treatment — must be counseled about this interaction and offered highly effective non-hormonal contraception or progestin-only methods not dependent on CYP metabolism (e.g., copper intrauterine device (IUD), levonorgestrel IUD). Preconception counseling for women with epilepsy or anxiety disorders on benzodiazepines should address planned discontinuation or transition to a safer agent before conception, optimal timing of pregnancy, and folate supplementation.
Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology — drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157–1167.
doi:10.1056/NEJMra035092Bhatt M, Johnson DW, Chan J, et al. Risk factors for adverse events in emergency department procedural sedation for children. JAMA Pediatr. 2017;171(10):957–964.
doi:10.1001/jamapediatrics.2017.2135Yuen VM, Hui TW, Irwin MG, Yuen MK. A comparison of intranasal dexmedetomidine and oral midazolam for premedication in pediatric anesthesia: a double-blinded randomized controlled trial. Anesth Analg. 2008;106(6):1715–1721.
doi:10.1213/ane.0b013e31816c8929Painter MJ, Scher MS, Stein AD, et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. N Engl J Med. 1999;341(7):485–489.
doi:10.1056/NEJM199908123410704Hudak ML, Tan RC; Committee on Drugs; Committee on Fetus and Newborn. Neonatal drug withdrawal. Pediatrics. 2012;129(2):e540–e560.
doi:10.1542/peds.2011-3212Greenblatt DJ, Harmatz JS, Shapiro L, Engelhardt N, Gouthro TA, Shader RI. Sensitivity to triazolam in the elderly. N Engl J Med. 1991;324(24):1691–1698.
doi:10.1056/NEJM199106133242403American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052–2081.
doi:10.1111/jgs.18372Mugunthan K, McGuire T, Glasziou P. Minimal interventions to decrease long-term use of benzodiazepines in primary care: a systematic review and meta-analysis. Br J Gen Pract. 2011;61(590):e573–e578.
doi:10.3399/bjgp11X593063Lembke A, Papac J, Humphreys K. Our other prescription drug problem. N Engl J Med. 2018;378(8):693–695.
doi:10.1056/NEJMp1715050Peckham AM, Evoy KE, Ochs L, Covvey JR. Gabapentin for off-label use: evidence-based or cause for concern? Subst Abuse. 2018;12:1178221818801311.
doi:10.1177/1178221818801311Wikner BN, Stiller CO, Bergman U, Asker C, Kallen B. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidemiol Drug Saf. 2007;16(11):1203–1210.
doi:10.1002/pds.1457